136 related articles for article (PubMed ID: 10400646)
21. Isolevuglandin-modified proteins, including elevated levels of inactive calpain-1, accumulate in glaucomatous trabecular meshwork.
Govindarajan B; Laird J; Salomon RG; Bhattacharya SK
Biochemistry; 2008 Jan; 47(2):817-25. PubMed ID: 18085799
[TBL] [Abstract][Full Text] [Related]
22. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro.
Lynch SM; Morrow JD; Roberts LJ; Frei B
J Clin Invest; 1994 Mar; 93(3):998-1004. PubMed ID: 8132786
[TBL] [Abstract][Full Text] [Related]
23. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
[TBL] [Abstract][Full Text] [Related]
24. Levuglandinyl adducts of proteins are formed via a prostaglandin H2 synthase-dependent pathway after platelet activation.
Boutaud O; Li J; Zagol I; Shipp EA; Davies SS; Roberts LJ; Oates JA
J Biol Chem; 2003 May; 278(19):16926-8. PubMed ID: 12637576
[TBL] [Abstract][Full Text] [Related]
25. Electrophilic levuglandin E2-protein adducts bind glycine: a model for protein crosslinking.
Jirousek MR; Murthi KK; Salomon RG
Prostaglandins; 1990 Aug; 40(2):187-203. PubMed ID: 2217833
[TBL] [Abstract][Full Text] [Related]
26. Formation of DNA-protein cross-links in mammalian cells by levuglandin E2.
Murthi KK; Friedman LR; Oleinick NL; Salomon RG
Biochemistry; 1993 Apr; 32(15):4090-7. PubMed ID: 8471616
[TBL] [Abstract][Full Text] [Related]
27. Generation and detection of levuglandins and isolevuglandins in vitro and in vivo.
Zhang M; Li W; Li T
Molecules; 2011 Jun; 16(7):5333-48. PubMed ID: 21705973
[TBL] [Abstract][Full Text] [Related]
28. Isolevuglandin-protein adducts in oxidized low density lipoprotein and human plasma: a strong connection with cardiovascular disease.
Salomon RG; Kaur K; Batyreva E
Trends Cardiovasc Med; 2000 Feb; 10(2):53-9. PubMed ID: 11150730
[TBL] [Abstract][Full Text] [Related]
29. Formation of F2-isoprostanes in oxidized low density lipoprotein: inhibitory effect of hydroxytyrosol.
Salami M; Galli C; De Angelis L; Visioli F
Pharmacol Res; 1995 May; 31(5):275-9. PubMed ID: 7479524
[TBL] [Abstract][Full Text] [Related]
30. The Adductomics of Isolevuglandins: Oxidation of IsoLG Pyrrole Intermediates Generates Pyrrole⁻Pyrrole Crosslinks and Lactams.
Bi W; Jang GF; Zhang L; Crabb JW; Laird J; Linetsky M; Salomon RG
High Throughput; 2019 May; 8(2):. PubMed ID: 31083423
[TBL] [Abstract][Full Text] [Related]
31. Stimulated arachidonate metabolism during foam cell transformation of mouse peritoneal macrophages with oxidized low density lipoprotein.
Yokode M; Kita T; Kikawa Y; Ogorochi T; Narumiya S; Kawai C
J Clin Invest; 1988 Mar; 81(3):720-9. PubMed ID: 3125226
[TBL] [Abstract][Full Text] [Related]
32. Levuglandin E2 inhibits mitosis and microtubule assembly.
Murthi KK; Salomon RG; Sternlicht H
Prostaglandins; 1990 Jun; 39(6):611-22. PubMed ID: 2115185
[TBL] [Abstract][Full Text] [Related]
33. Cellular mechanisms of lipid injury in the glomerulus.
Schlondorff D
Am J Kidney Dis; 1993 Jul; 22(1):72-82. PubMed ID: 8322798
[TBL] [Abstract][Full Text] [Related]
34. Do E-series prostaglandins and their metabolites influence oxidation of native and glycated low-density lipoproteins?
Sobal G; Menzel JE; Sinzinger H
Prostaglandins Other Lipid Mediat; 1998 Jan; 55(1):67-76. PubMed ID: 9661219
[TBL] [Abstract][Full Text] [Related]
35. Measurement of chronic oxidative and inflammatory stress by quantification of isoketal/levuglandin gamma-ketoaldehyde protein adducts using liquid chromatography tandem mass spectrometry.
Davies SS; Amarnath V; Brame CJ; Boutaud O; Roberts LJ
Nat Protoc; 2007; 2(9):2079-91. PubMed ID: 17853863
[TBL] [Abstract][Full Text] [Related]
36. Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives.
Rubbo H; Parthasarathy S; Barnes S; Kirk M; Kalyanaraman B; Freeman BA
Arch Biochem Biophys; 1995 Dec; 324(1):15-25. PubMed ID: 7503550
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel class of endoperoxides from arachidonate autoxidation.
Yin H; Morrow JD; Porter NA
J Biol Chem; 2004 Jan; 279(5):3766-76. PubMed ID: 14594817
[TBL] [Abstract][Full Text] [Related]
38. Prostaglandins and lipid modification.
Sobal G; Sinzinger H
Curr Pharm Des; 2001 Apr; 7(6):461-74. PubMed ID: 11281853
[TBL] [Abstract][Full Text] [Related]
39. Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts.
Li W; Laird JM; Lu L; Roychowdhury S; Nagy LE; Zhou R; Crabb JW; Salomon RG
Free Radic Biol Med; 2009 Dec; 47(11):1539-52. PubMed ID: 19751823
[TBL] [Abstract][Full Text] [Related]
40. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite.
Moore KP; Darley-Usmar V; Morrow J; Roberts LJ
Circ Res; 1995 Aug; 77(2):335-41. PubMed ID: 7614720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
